Veracyte IncVCYT
Price$46.04Intrinsic value$26.7842% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $561.9M+26.1% YoYTTM through 30 Jun 2026
Net Income $114.5M+374.3% YoYTTM through 30 Jun 2026
Free Cash Flow $166MTTM through 30 Jun 2026

Margins

Current
Gross Margin73.0%
EBITDA Margin22.5%
Operating Margin16.3%
Net Margin20.4%

Returns

6.6%ROE
6.1%ROA
10.5%ROIC

Balance Sheet Health

Debt / Equity0.00x
Current Ratio8.13x
Net Debt-$439.1Mnet cash position
Cash & Equivalents$299.5M

Quality Metrics

Altman Z-Score22.07
Piotroski F-Score6 / 9
FCF Margin29.5%
Rule of 4035.2
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $517.1M
Diluted EPS$1.40TTM
'19'20'21'22'23'24'25
FY2025: $0.82

Dividend

No dividend

Capital Allocation

R&D Spend$93.4M
Capex Intensity2.2%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.